Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 73.7 | 63.1 | 44.5 | 34.9 |
| Revenue growth | 16.7% | 41.8% | 27.5% | |
| Cost of goods sold | 30.8 | 32.1 | 14.6 | 0.0 |
| Gross profit | 42.9 | 31.1 | 29.9 | 34.9 |
| Gross margin | 58.2% | 49.2% | 67.2% | 100.0% |
| Selling, general and administrative | 59.5 | 39.8 | 22.1 | 19.1 |
| Research and development | 10.9 | 2.7 | | |
| EBITA | -23.2 | -32.4 | 9.3 | 5.3 |
| EBITA margin | -31.5% | -51.3% | 20.8% | 15.1% |
| Amortization of intangibles | 4.3 | 2.5 | 1.4 | |
| EBIT | -27.5 | -34.9 | 7.9 | 5.3 |
| EBIT margin | -37.4% | -55.2% | 17.6% | 15.1% |
| Pre-tax income | -29.6 | -42.4 | 7.2 | 5.0 |
| Income taxes | 0.1 | 1.6 | 1.9 | 1.4 |
| Tax rate | | | 26.1% | 27.6% |
| Net income | -29.6 | -44.0 | 5.3 | 0.0 |
| Net margin | -40.2% | -69.7% | 11.9% | 0.0% |
| |
| Diluted EPS | ($1.69) | ($4.32) | $0.49 | |
| Shares outstanding (diluted) | 17.5 | 10.2 | 10.8 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|